Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Cancer
|
September 15, 1994
Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial
R J Packer, J M Boyett, R A Zimmerman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group
I J Dunkel, J M Boyett, A Yates, et al.
Leukemia
|
April 18, 2002
Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report
M S Cairo, M D Krailo, M Morse, et al.
Journal of Neurosurgery
|
July 1, 1998
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945
J H Wisoff, J M Boyett, M S Berger, et al.
Bone Marrow Transplantation
|
August 5, 2000
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors
V Papadakis, I J Dunkel, L D Cramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors
W P Mason, A Grovas, S Halpern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1996
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group
J L Finlay, S Goldman, M C Wong, et al.
Journal of Neurosurgery
|
April 3, 1998
Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group
P L Robertson, P M Zeltzer, J M Boyett, et al.
Pediatric Neurosurgery
|
January 1, 1996
Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study
M Deutsch, P R Thomas, J Krischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study
P M Zeltzer, J M Boyett, J L Finlay, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Cancer
|
September 15, 1994
Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial
R J Packer, J M Boyett, R A Zimmerman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group
I J Dunkel, J M Boyett, A Yates, et al.
Leukemia
|
April 18, 2002
Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report
M S Cairo, M D Krailo, M Morse, et al.
Journal of Neurosurgery
|
July 1, 1998
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945
J H Wisoff, J M Boyett, M S Berger, et al.
Bone Marrow Transplantation
|
August 5, 2000
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors
V Papadakis, I J Dunkel, L D Cramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors
W P Mason, A Grovas, S Halpern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1996
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group
J L Finlay, S Goldman, M C Wong, et al.
Journal of Neurosurgery
|
April 3, 1998
Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group
P L Robertson, P M Zeltzer, J M Boyett, et al.
Pediatric Neurosurgery
|
January 1, 1996
Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study
M Deutsch, P R Thomas, J Krischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study
P M Zeltzer, J M Boyett, J L Finlay, et al.
Page
of 11